Aeglea BioTherapeutics, Inc.
|
(Name of Issuer)
|
Common Stock, par value $0.0001 per share
|
(Title of Class of Securities)
|
00773J 103
|
(CUSIP Number)
|
April 6, 2016
|
(Date of Event Which Requires Filing of this Statement)
|
☐ | Rule 13d-1(b) |
☒ | Rule 13d-1(c) |
☐ | Rule 13d-1(d) |
CUSIP No. [●]
|
13G
|
Page 2 of 6 Pages
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
Novartis Bioventures Ltd.
|
|
|
|||
|
|
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
||||
(a)☐
|
|||||
(b)☐
|
|
|
|||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
Bermuda
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
0
|
|
|
|||
|
|
||||
6
|
SHARED VOTING POWER
|
|
|
||
2,310,924
|
|
|
|||
|
|
||||
7
|
SOLE DISPOSITIVE POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
8
|
SHARED DISPOSITIVE POWER
|
|
|
||
2,310,924
|
|
|
|||
|
|
||||
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
2,310,924
|
|
|
|||
|
|
||||
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
||
☐
|
|
|
|||
|
|
||||
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
||
17.2%
|
|
|
|||
|
|
||||
12
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
CO
|
|
|
|||
|
|
CUSIP No. [●]
|
13G
|
Page 3 of 6 Pages
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
Novartis AG
|
|
|
|||
|
|
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
||||
(a)☐
|
|||||
(b)☐
|
|
|
|||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
Switzerland
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
0
|
|
|
|||
|
|
||||
6
|
SHARED VOTING POWER
|
|
|
||
2,310,924
|
|
|
|||
|
|
||||
7
|
SOLE DISPOSITIVE POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
8
|
SHARED DISPOSITIVE POWER
|
|
|
||
2,310,924
|
|
|
|||
|
|
||||
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
2,310,924
|
|
|
|||
|
|
||||
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
||
☐
|
|
|
|||
|
|
||||
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
||
17.2%
|
|
|
|||
|
|
||||
12
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
CO
|
|
|
|||
|
|
Item 1(a). | Name of Issuer: |
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
Item 2(a). | Name of Person Filing: |
Item 2(b). | Address of Principal Business Office or, if none, Residence: |
Item 2(c). | Citizenship: |
Item 2(d). | Title of Class of Securities: |
Item 2(e). | CUSIP Number: |
Item 3. | If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: |
(a) ☐
|
Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
|
(b) ☐
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
(c) ☐
|
Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);
|
(d) ☐
|
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
|
(e) ☐
|
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
(f) ☐
|
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
(g) ☐
|
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
(h) ☐
|
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
(i) ☐
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
(j) ☐
|
A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
|
(k) ☐
|
Group, in accordance with §240.13d–1(b)(1)(ii)(K).
|
Item 4. | Ownership |
(a) | Amount Beneficially Owned: |
(b) | Percent of Class: |
(c) | Number of shares as to which the person has: |
(i) | Sole power to vote or to direct the vote: Not applicable |
(ii) | Shared power to vote or to direct the vote: 2,310,924 |
(iii) | Sole power to dispose or to direct the disposition of: Not applicable |
(iv) | Shared power to dispose or to direct the disposition of: 2,310,924 |
Item 5. | Ownership of 5 Percent or Less of a Class |
Item 6. | Ownership of More than 5 Percent on Behalf of Another Person |
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. |
Item 8. | Identification and Classification of Members of the Group |
Item 9. | Notice of Dissolution of a Group |
Item 10. | Certification |
Date: April 13, 2016
|
||
Novartis Bioventures Ltd.
|
||
/s/ Simon Zivi
|
||
Name: Title: Chairman
|
||
/s/ Laurieann Chaikowsky
|
||
Name: Laurieann Chaikowsky
|
||
Title: Authorized Signatory
|
Novartis AG
|
||
/s/ Simon Zivi
|
||
Name: Simon Zivi
|
||
Title: Authorized Signatory
|
||
/s/ Laurieann Chaikowsky
|
||
Name: Laurieann Chaikowsky
|
||
Title: Authorized Signatory
|
Exhibit Number
|
Exhibit Description
|
Evidence of Signature Authority
|
|
Power of Attorney
|
|
Joint Filing Agreement
|